Chikungunya has been identified in over 60 countries in Asia, Africa. Europe and the Americas. After the bite of an infected mosquito, onset of illness occurs usually between 4 and 8 days but can range from 2 to 12 days. In some people, the joint pain may persist for months. People at risk for severe indications include new borns infected around the time of birth, older adults (below 65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.
Since 2005, India, Indonesia, Maldives, Myanmar and Thai land have reported over 1.9 mi llion cases' and almost 1.3 million' suspected cases of Chikungunya being recorded in the Caribbean islands, Latin American countries, and the United States of America till 201 5.
Speaking on this key development, Pankaj R. Patel, Chairman and Managing Director, Zydus group said, "We have always been committed to working with partners and collaborating to bring affordable therapies and bridge unmet healthcare needs. By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all important step to prevent the disease burden which is highly prevalent in developing countries and causes suffering and disability."
Dr. Rahul Singhvi, Takeda Vaccines' Chief Operating Officer said, “Takeda is very pleased to work with Zydus Cadila. We are always open to tackling the world's most urgent and neglected unmet medical needs together with partners. Our belief is that chikungunya can be prevented by vaccines, and that a vaccine might be licensed more quickly if we can accelerate development with this Zydus partnership."
Dr. Singhvi added, "Takeda is at the center of important vaccine-related activities i n global health and emerging infectious diseases. This is another demonstration or Takeda's major commitment to the health of children in developing countries and elsewhere around the world."
Terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future through this novel partnership.